KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Operating Leases: 2019-2024

Historic Operating Leases for Nektar Therapeutics (NKTR) over the last 6 years, with Dec 2024 value amounting to $82.7 million.

  • Nektar Therapeutics' Operating Leases fell 19.62% to $69.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.7 million, marking a year-over-year decrease of 19.62%. This contributed to the annual value of $82.7 million for FY2024, which is 16.06% down from last year.
  • As of FY2024, Nektar Therapeutics' Operating Leases stood at $82.7 million, which was down 16.06% from $98.5 million recorded in FY2023.
  • Nektar Therapeutics' Operating Leases' 5-year high stood at $136.4 million during FY2020, with a 5-year trough of $82.7 million in FY2024.
  • Over the past 3 years, Nektar Therapeutics' median Operating Leases value was $98.5 million (recorded in 2023), while the average stood at $98.0 million.
  • Data for Nektar Therapeutics' Operating Leases shows a maximum YoY declined of 16.06% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Nektar Therapeutics' Operating Leases stood at $136.4 million in 2020, then decreased by 7.80% to $125.7 million in 2021, then dropped by 10.27% to $112.8 million in 2022, then fell by 12.68% to $98.5 million in 2023, then declined by 16.06% to $82.7 million in 2024.